Recent Posts
- HealthInvest June 2026: A Look Inside Australia’s Healthcare Innovations
- HealthInvest Returns for 2026: Meet the Companies Shaping Australian Life Sciences
- Lifesaving Capital: How impact investing is shaping the future of biotech
- Investor Relations: the quiet advantage powering ASX microcaps
- HealthInvest Sydney: Life Sciences in the Investor Spotlight
Archives
Tesserent presents at IRD Invest

On 14 October 2020, Tesserent CEO, Julian Challingsworth presented at IR Department’s virtual investor conference, IRD Invest, an event designed to bring investors directly to the CEOs of emerging ASX listed companies.
Jaxsta presents at IRD Invest

On 14 October 2020, Jaxsta CEO and co-founder, Jacqui Louez Schoorl and Jaxsta CFO, Company Secretary and Executive Director Jorge Nigaglioni, presented at IR Department’s virtual investor conference, IRD Invest, an event designed to bring investors directly to the CEOs of emerging ASX listed companies.
Openpay presents at IRD Invest

Openpay Group Ltd (ASX: OPY) is a well-established player in the fast-growing global market for ‘Buy now pay later’ (BNPL) payment solutions. Openpay partners with merchants to provide BNPL repayment plans to customers instore, in-app and online.
Oventus presents at IRD Invest

On 14 October 2020, Oventus CEO, Dr Chris Hart, presented at IR Department’s virtual investor conference, IRD Invest, an event designed to bring investors directly to the CEOs of emerging ASX listed companies.
Technology 2020

Kazia achieves major milestones

Our client, ASX-listed oncology company Kazia Therapeutics Ltd (ASX: KZA; NASDAQ: KZIA, has had a huge few months, including the achievement of significant milestones for lead drug candidate, paxalisib.
- 1
